Were Analysts Bullish Argos Therapeutics Inc (NASDAQ:ARGS) This Week?

July 17, 2017 - By Peter Erickson

 Were Analysts Bullish Argos Therapeutics Inc (NASDAQ:ARGS) This Week?
Investors sentiment increased to 2.7 in Q4 2016. Its up 0.14, from 2.56 in 2016Q3. It improved, as 2 investors sold Argos Therapeutics Inc shares while 8 reduced holdings. 8 funds opened positions while 19 raised stakes. 7.25 million shares or 21.41% more from 5.97 million shares in 2016Q3 were reported.
The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Wall Street Assocs holds 0.27% of its portfolio in Argos Therapeutics Inc (NASDAQ:ARGS) for 82,850 shares. 51,285 are held by Morgan Stanley. Amer Inc holds 6,131 shares. 94,800 are owned by California Public Employees Retirement. Moreover, Susquehanna Grp Limited Liability Partnership has 0% invested in Argos Therapeutics Inc (NASDAQ:ARGS) for 1.02M shares. Bridgeway Capital Mngmt Inc reported 121,524 shares. Moreover, Keybank Natl Association Oh has 0% invested in Argos Therapeutics Inc (NASDAQ:ARGS) for 24,358 shares. Schwab Charles Management Incorporated reported 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Citigroup has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Royal National Bank & Trust Of Canada holds 1,726 shares. Goldman Sachs reported 13,399 shares. Millennium Ltd has 143,113 shares. Nationwide Fund Advsrs, Pennsylvania-based fund reported 11,678 shares. 1,788 are owned by Legal General Gru Public Lc.

Argos Therapeutics Inc (NASDAQ:ARGS) Ratings Coverage

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Argos Therapeutics had 5 analyst reports since November 16, 2015 according to SRatingsIntel. FBR Capital maintained it with “Outperform” rating and $17 target in Monday, November 16 report. FBR Capital maintained it with “Outperform” rating and $13 target in Thursday, August 11 report. The stock has “Buy” rating by Roth Capital on Tuesday, April 19. The stock has “Buy” rating by Needham on Tuesday, November 17. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. Below is a list of Argos Therapeutics Inc (NASDAQ:ARGS) latest ratings and price target changes.

It closed at $0.308 lastly. It is down 92.57% since July 17, 2016 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has market cap of $12.41 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

More notable recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Globenewswire.com which released: “Argos Therapeutics Enters into Strategic Research Agreement with Personalis, Inc.” on December 14, 2016, also Seekingalpha.com with their article: “Argos Therapeutics: What’s In Store After ADAPT’s Failure?” published on February 27, 2017, Streetinsider.com published: “Argos Therapeutics (ARGS) Announces Interim Results of ADAPT Trial; to …” on April 18, 2017. More interesting news about Argos Therapeutics Inc (NASDAQ:ARGS) were released by: Globenewswire.com and their article: “Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note …” published on June 22, 2017 as well as Seekingalpha.com‘s news article titled: “Argos Therapeutics: Interview With CEO Jeff Abbey And VP Communications John …” with publication date: February 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.